Pulmonary Arterial Hypertension (PAH) Panel, Sequencing and Deletion/Duplication
Preferred test to confirm diagnosis of pulmonary arterial hypertension (PAH), especially in those with a family history of PAH.
New York DOH Approval Status
Lavender or pink (EDTA) or yellow (ACD solution A or B).
New York State Clients: Lavender (EDTA)
Transport 3 mL whole blood. (Min: 3 mL)
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
New York State Clients: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
Massively Parallel Sequencing
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Genes tested: ACVRL1, BMPR2, CAV1, EIF2AK4, ENG,* GDF2, KCNA5, KCNK3, SMAD9, TBX4
*One or more exons are not covered by deletion/duplication analysis for the indicated gene; see Additional Technical Information.
81405; 81406; 81479
|Component Test Code*||Component Chart Name||LOINC|
|2009346||PAH Pan. Seq/DelDup, Specimen||31208-2|
|2009349||PAH Pan. Seq/DelDup, Interp||49014-4|
- increased mean pulmonary artery pressure
- pulmonary arterial hypertension